Precision BioSciences (DTIL) Projected to Post Quarterly Earnings on Wednesday

Precision BioSciences (NASDAQ:DTIL) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Precision BioSciences to post earnings of ($2.09) per share and revenue of $4.28 million for the quarter.

Precision BioSciences Stock Up 1.7 %

Shares of NASDAQ:DTIL opened at $5.45 on Monday. The company has a 50 day moving average of $5.14 and a 200-day moving average of $6.68. Precision BioSciences has a one year low of $3.61 and a one year high of $15.97. The stock has a market cap of $41.81 million, a price-to-earnings ratio of 90.85 and a beta of 1.59. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Insider Buying and Selling at Precision BioSciences

In other news, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the completion of the transaction, the chief executive officer now owns 107,087 shares of the company’s stock, valued at $500,096.29. The trade was a 25.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider J. Jefferson Smith sold 10,287 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total value of $49,274.73. Following the sale, the insider now directly owns 87,440 shares in the company, valued at $418,837.60. The trade was a 10.53 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 8,734 shares of company stock valued at $39,946 and sold 47,279 shares valued at $222,064. Insiders own 4.00% of the company’s stock.

Wall Street Analysts Forecast Growth

DTIL has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research report on Wednesday, March 19th. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a report on Friday, January 10th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.